US2358511028
© PR Newswire
09.12.2025
DHR
LISTED
NYSE
Danaher Announces Quarterly Dividend
News Preview
WASHINGTON, Dec. 9, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on January 30, 2026 to holders of record on December 26, 2025.
ABOUT DANAHERDanaher is a leading global life sciences and diagnostics inn...
Themefolio
Profiler
Peergroup
© PR Newswire
11.11.2025
DHR
LISTED
NYSE
Danaher to Present at Jefferies Global Healthcare Conference
News Preview
WASHINGTON, Nov. 11, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Jefferies Global Healthcare Conference in London, UK on Tuesday, November 18, 2025 at 11:00 a.m. GMT. The event will be simultaneously webcast...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
DHR
LISTED
NYSE
DHR Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR
News Preview
Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR).
If you currently own shares of Danaher stock, please visit the firm’s website at https://rosenlegal.com/submit-form/?case_id=17717 for more information. You may also...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
24.10.2025
DHR
LISTED
NYSE
Halper Sadeh LLC Encourages Danaher Corporation Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Danaher Corporation (NYSE: DHR) breached their fiduciary duties to shareholders.
If you currently own Danaher stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the compan...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
21.10.2025
DHR
LISTED
NYSE
Danaher Reports Third Quarter 2025 Results
News Preview
WASHINGTON, Oct. 21, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 26, 2025.
Key Third Quarter 2025 Results
Net earnings were $908 million, or $1.27...
Themefolio
Profiler
Peergroup
© BusinessWire
26.09.2025
DHR
LISTED
NYSE
DANAHER INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Danaher Corporation - DHR
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Danaher Corporation (NYSE: DHR).
On April 25, 2023, the Company disclosed that "[r]evenues decreased 7.0% year-over-year to $7.2 billion, with a 4.0% non-GAAP co...
Themefolio
Profiler
Peergroup
© PR Newswire
23.09.2025
DHR
LISTED
NYSE
Danaher Schedules Third Quarter 2025 Earnings Conference Call
News Preview
WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2025 on Tuesday, October 21, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as futur...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2025
DHR
LISTED
NYSE
Beckman Coulter Diagnostics Launches Industry First Fully Automated, High Throughput BD-Tau Research Use Only Immunoassay Test, Advancing Neurodegenerative Clinical Research
News Preview
Beckman Coulter Also Announces Development of Aß-42 Research Use Only Immunoassay Test
BREA, Calif., Sept. 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and a leader in global clinical diagnostics innovation, today launched the industry's first fully automated Brain-derived Tau (BD-Tau) research use only (RUO) immunoassa...
Themefolio
Profiler
Peergroup
© PR Newswire
09.09.2025
DHR
LISTED
NYSE
Danaher Announces Quarterly Dividend
News Preview
WASHINGTON, Sept. 9, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on October 31, 2025 to holders of record on September 26, 2025.
ABOUT DANAHERDanaher is a leading global life sciences and diagnostics...
Themefolio
Profiler
Peergroup
© BusinessWire
02.09.2025
DHR
LISTED
NYSE
DANAHER INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Danaher Corporation - DHR
News Preview
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Danaher Corporation (NYSE: DHR).
On April 25, 2023, the Company disclosed that "[r]evenues decreased 7.0% year-over-year to $7.2 billion, with a 4.0% non-GAAP co...
Themefolio
Profiler
Peergroup
© PR Newswire
31.07.2025
DHR
LISTED
NYSE
Danaher Appoints Jonathan Leiken as General Counsel
News Preview
WASHINGTON, July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and...
Themefolio
Profiler
Peergroup
© PR Newswire
22.07.2025
DHR
LISTED
NYSE
Danaher Announces Transition Plan for Chief Financial Officer
News Preview
WASHINGTON, July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as D...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
22.07.2025
DHR
LISTED
NYSE
Danaher Reports Second Quarter 2025 Results
News Preview
WASHINGTON, July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 27, 2025.
Key Second Quarter 2025 Results
Net earnings were $555 million, or $0.77 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.80.Revenues increased 3.5% yea...
Themefolio
Profiler
Peergroup
© PR Newswire
27.06.2025
DHR
LISTED
NYSE
Danaher Appoints Martin Stumpe as Chief Technology and AI Officer
News Preview
WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer.
This appointment mark...
Themefolio
Profiler
Peergroup
© PR Newswire
27.06.2025
DHR
LISTED
NYSE
Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences
News Preview
WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025.
Mr. Milosevich...
Themefolio
Profiler
Peergroup
© PR Newswire
17.06.2025
DHR
LISTED
NYSE
Danaher Schedules Second Quarter 2025 Earnings Conference Call
News Preview
WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future e...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
DHR
LISTED
NYSE
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
News Preview
At ASMS 2025, SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
DHR
LISTED
NYSE
Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations
News Preview
SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), announces three software ecosystem enhancements at ASMS. These developments will present new ways to acquire data, new standards for performance, and new practices to extract elevated insights, all supporting the theme that “all...
Themefolio
Profiler
Peergroup
© BusinessWire
02.06.2025
DHR
LISTED
NYSE
SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement
News Preview
SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE: DHR), and Evosep Biosystems, a global leader in proteomics solutions, enter a reseller agreement to co-sell SCIEX mass spectrometry systems with the newly announced Evosep Eno, for standardized high-throughput proteomics.
The resell...
Themefolio
Profiler
Peergroup
© BusinessWire
15.05.2025
DHR
LISTED
NYSE
Aldevron and Integrated DNA Technologies Manufacture World’s First mRNA-based Personalized CRISPR Therapy
News Preview
Aldevron, a global leader in the production of DNA, RNA and protein, together with Integrated DNA Technologies (IDT), a global leader in genomics solutions, announced the successful manufacture of the world’s first personalized CRISPR gene editing drug product to treat an infant with urea cycle disorder (UCD). With no current cure for UCDs, the Ch...
Themefolio
Profiler
Peergroup
© PR Newswire
07.05.2025
DHR
LISTED
NYSE
Danaher to Present at Bank of America Securities Healthcare Conference
News Preview
WASHINGTON, May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Thursday, May 15, 2025 at 10:00 a.m. PT. The event will be simultaneously webcast on www.danaher.c...
Themefolio
Profiler
Peergroup
© PR Newswire
06.05.2025
DHR
LISTED
NYSE
Danaher Announces Quarterly Dividend
News Preview
WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025.
ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator...
Themefolio
Profiler
Peergroup
© PR Newswire
29.04.2025
DHR
LISTED
NYSE
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
News Preview
Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.
High transgene expression and improved safety profile of Aldveron's Nanoplasmid™ vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx™ platform with unlimited scale, together offer enhanced CRISPR-med...
Themefolio
Profiler
Peergroup
© PR Newswire
22.04.2025
DHR
LISTED
NYSE
Danaher Reports First Quarter 2025 Results
News Preview
WASHINGTON, April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025.
Key First Quarter 2025 Results
Net earnings were $1.0 billion, or $1.32 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.88.Revenues decreased 1.0% to...
Themefolio
Profiler
Peergroup
© PR Newswire
20.03.2025
DHR
LISTED
NYSE
Danaher Schedules First Quarter 2025 Earnings Conference Call
News Preview
WASHINGTON, March 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the first quarter 2025 on Tuesday, April 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future...
Themefolio
Profiler
Peergroup
© PR Newswire
10.03.2025
DHR
LISTED
NYSE
Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System
News Preview
The new DxC 500i Analyzer Offers Flexibility and Scalability with Broad Chemistry and Immunoassay Assay Menu
BREA, Calif., March 10, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a clinical diagnostics leader, today announced that the new DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer, received 510(k) cl...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
DHR
LISTED
NYSE
Danaher to Present at TD Cowen Health Care Conference
News Preview
WASHINGTON, Feb. 25, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the TD Cowen Healthcare Conference in Boston, Massachusetts on Wednesday, March 5, 2025 at 10:30 a.m. ET. The event will be simultaneously webcast and can be accessed on the "Invest...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
DHR
LISTED
NYSE
Danaher Announces Appointment of Charles Lamanna to Danaher Board
News Preview
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Charles Lamanna to its Board of Directors and to the Board's Science & Technology Committee.
Mr. Lamanna is currently Corporate Vice President, Business & Industry Copilot at Microsoft (NASDAQ: MSFT), where he drives product in...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
DHR
LISTED
NYSE
Danaher Increases Quarterly Dividend
News Preview
WASHINGTON, Feb. 20, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on April 25, 2025 to holders of record on March 28, 2025. This reflects an 18.5% increase over the previous dividend payment of $0.27....
Themefolio
Profiler
Peergroup
© PR Newswire
29.01.2025
DHR
LISTED
NYSE
Danaher Reports Fourth Quarter and Full Year 2024 Results
News Preview
WASHINGTON, Jan. 29, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2024. All results in this release reflect only continuing operations unless otherwise noted.
Key Fourth Quarter 2024 Results
Net earnings were $1.1 billion, or $1.49 per diluted common share and...
Themefolio
Profiler
Peergroup
© PR Newswire
15.01.2025
DHR
LISTED
NYSE
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
News Preview
New, Fully Automated, High-Throughput RUO Assays offered on Beckman Coulter Immunoassay Analyzers
BREA, Calif., Jan. 15, 2025 /PRNewswire/ -- Beckman Coulter Diagnostics, a global leader in advanced diagnostics, today announced availability of new Research Use Only (RUO) blood-based biomarker immunoassays designed to advance neurodegenerative di...
Themefolio
Profiler
Peergroup
© PR Newswire
13.01.2025
DHR
LISTED
NYSE
Danaher CEO to Comment on Financial Performance
News Preview
WASHINGTON, Jan. 13, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced that its President and Chief Executive Officer, Rainer M. Blair, will comment tomorrow on the Company's fourth quarter 2024 performance in a presentation at the J.P. Morgan Healthcare Conference at 11:15 a.m. PT.
For the fourth quarter 2024, estim...
Themefolio
Profiler
Peergroup
© PR Newswire
06.01.2025
DHR
LISTED
NYSE
Danaher to Present at J.P. Morgan Healthcare Conference
News Preview
WASHINGTON, Jan. 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that its President and Chief Executive Officer, Rainer M. Blair, will be presenting at the J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 14, 2025 at 11:15 a.m. PT. The event will be simultaneously webcast and can be accessed on...
Themefolio
Profiler
Peergroup
© PR Newswire
02.01.2025
DHR
LISTED
NYSE
Danaher Schedules Fourth Quarter 2024 Earnings Conference Call
News Preview
WASHINGTON, Jan. 2, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the fourth quarter 2024 on Wednesday, January 29, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as futu...
Themefolio
Profiler
Peergroup
© PR Newswire
10.12.2024
DHR
LISTED
NYSE
Danaher Announces Quarterly Dividend
News Preview
WASHINGTON, Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on January 31, 2025 to holders of record on December 27, 2024.
ABOUT DANAHERDanaher is a leading global life sciences and diagnostics...
Themefolio
Profiler
Peergroup
© PR Newswire
26.11.2024
DHR
LISTED
NYSE
Danaher to Present at Evercore ISI HealthCONx Conference
News Preview
WASHINGTON, Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Wednesday, December 4, 2024 at 3:25 p.m. ET. The event will be simultaneously webcast on www.danaher.com.
ABOUT D...
Themefolio
Profiler
Peergroup
© PR Newswire
22.10.2024
DHR
LISTED
NYSE
Danaher Reports Third Quarter 2024 Results
News Preview
WASHINGTON, Oct. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended September 27, 2024. All results in this release reflect only continuing operations unless otherwise noted.
Key Third Quarter 2024 Results
Net earnings were $818 million, or $1.12 per diluted common share and no...
Themefolio
Profiler
Peergroup
© PR Newswire
19.09.2024
DHR
LISTED
NYSE
Danaher Schedules Third Quarter 2024 Earnings Conference Call
News Preview
WASHINGTON, Sept. 19, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2024 on Tuesday, October 22, 2024 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as futur...
Themefolio
Profiler
Peergroup
© PR Newswire
17.09.2024
DHR
LISTED
NYSE
Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
News Preview
BREA, Calif. and TEL AVIV, Israel, Sept. 17, 2024 /PRNewswire/ -- Beckman Coulter, a clinical diagnostics leader, and Scopio Labs, a medtech company that develops digital cell morphology workflow solutions, today jointly announced expansion of its long-term partnership to include a global distribution agreement of Scopio's Full-Field Bone Marrow...
Themefolio
Profiler
Peergroup
© PR Newswire
10.09.2024
DHR
LISTED
NYSE
Danaher Announces Quarterly Dividend
News Preview
WASHINGTON, Sept. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on October 25, 2024 to holders of record on September 27, 2024.
ABOUT DANAHERDanaher is a leading global life sciences and diagnostic...
Themefolio
Profiler
Peergroup
© PR Newswire
04.09.2024
DHR
LISTED
NYSE
Danaher Confirms Third Quarter and Full Year 2024 Guidance
News Preview
WASHINGTON, Sept. 4, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.
The Company provides forecasted sales only on a non-GAAP core revenue basis because of the difficulty in estimating the other co...
Themefolio
Profiler
Peergroup
© PR Newswire
26.08.2024
DHR
LISTED
NYSE
Danaher to Webcast Diagnostics Investor & Analyst Meeting in Washington, D.C.
News Preview
WASHINGTON, Aug. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Diagnostics Investor and Analyst Meeting in Washington, D.C. on September 5, 2024 beginning at approximately 10:00 a.m. ET. The event will be hosted by Julie Sawyer Montgomery, Executive Vice President, Diagnostics. A link to the webcas...
Themefolio
Profiler
Peergroup
© PR Newswire
23.07.2024
DHR
LISTED
NYSE
Danaher Reports Second Quarter 2024 Results
News Preview
WASHINGTON, July 23, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended June 28, 2024. All results in this release reflect only continuing operations unless otherwise noted.
Key Second Quarter 2024 Results
Net earnings were $907 million, or $1.22 per diluted common share and non-GA...
Themefolio
Profiler
Peergroup
© PR Newswire
17.07.2024
DHR
LISTED
NYSE
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
News Preview
DH Diagnostics LLC Centers aim to accelerate drug development by speeding and streamlining development and commercialization of companion diagnostics.Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP)-certified laboratories will bring technologies and assays from multiple Danaher subsidiaries together und...
Themefolio
Profiler
Peergroup
© PR Newswire
16.07.2024
DHR
LISTED
NYSE
Danaher Releases 2024 Sustainability Report
News Preview
WASHINGTON, July 16, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), the global life sciences and diagnostics innovator, today published its 2024 Sustainability Report which conveys the depth and scope of Danaher's sustainability program and highlights important milestones the Company achieved during the past ye...
Themefolio
Profiler
Peergroup
© PR Newswire
11.07.2024
DHR
LISTED
NYSE
Danaher Launches Beacon Research Collaboration with Stanford University Aiming to Build Next Generation of Smart Microscopes for Cancer Drug Screening
News Preview
Predictive tools will seek to reduce leading cause of failure rates in clinical trials of oncology drugs. Integrated AI and microscopy expected to lead to better understanding of tumor structures and treatment strategies.New technology will work to capture and analyze the highly heterogeneous tumor microenvironment.WASHINGTON, July 11, 2024 /PRNe...
Themefolio
Profiler
Peergroup
© PR Newswire
09.07.2024
DHR
LISTED
NYSE
Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
News Preview
Ideally Suited for Satellite and Independent Labs, the new DxC 500i Analyzer Offers Flexibility, Scalability and Data Commutability with Extensive Chemistry and Immunoassay Assay Menu
The New DxC 500i Analyzer Incorporates Recently Introduced DxC 500 AU Chemistry Analyzer Technology with Six Sigma Performance
BREA, Calif., July 9, 2024 /PRNewswir...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
